MX2022003823A - Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof. - Google Patents

Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof.

Info

Publication number
MX2022003823A
MX2022003823A MX2022003823A MX2022003823A MX2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A
Authority
MX
Mexico
Prior art keywords
sub
compositions
subtypes
methods
gaba
Prior art date
Application number
MX2022003823A
Other languages
Spanish (es)
Inventor
Andrew D Levin
Neil Buckley
Original Assignee
Eliem Therapeutics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eliem Therapeutics Uk Ltd filed Critical Eliem Therapeutics Uk Ltd
Publication of MX2022003823A publication Critical patent/MX2022003823A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABA<sub>A</sub> receptors, such as preferential modulation of α4β3δ GABA<sub>A</sub> receptors over α1β2γ2 GABA<sub>A</sub> receptors. The invention also provides methods of treating GABA<sub>A</sub> disorders using such compositions.
MX2022003823A 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof. MX2022003823A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962907763P 2019-09-30 2019-09-30
PCT/US2020/052167 WO2021067089A1 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022003823A true MX2022003823A (en) 2022-08-17

Family

ID=75338529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003823A MX2022003823A (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof.

Country Status (9)

Country Link
EP (1) EP4135710A4 (en)
JP (1) JP2022552788A (en)
KR (1) KR20220103707A (en)
CN (1) CN115087450A (en)
BR (1) BR112022006085A2 (en)
CA (1) CA3159087A1 (en)
IL (1) IL291835A (en)
MX (1) MX2022003823A (en)
WO (1) WO2021067089A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161530A4 (en) * 2020-06-08 2024-06-26 Eliem Therapeutics (UK) Ltd Methods of treating female health conditions related to sex hormones
WO2024020953A1 (en) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR102239541B1 (en) * 2013-04-17 2021-04-14 세이지 테라퓨틱스, 인크. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
BR112017007902B1 (en) * 2014-10-16 2023-12-05 Sage Therapeutics, Inc COMPOUND AND ITS SALT, PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND AND ITS SALT IN THE MANUFACTURE OF A MEDICINE FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
AU2017342521A1 (en) * 2016-10-14 2019-04-18 Marinus Pharmaceuticals, Inc Method of administering a neurosteroid to effect electroencephalographic (EEG) burst suppression
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof

Also Published As

Publication number Publication date
IL291835A (en) 2022-06-01
CN115087450A (en) 2022-09-20
EP4135710A1 (en) 2023-02-22
CA3159087A1 (en) 2021-04-08
JP2022552788A (en) 2022-12-20
WO2021067089A1 (en) 2021-04-08
EP4135710A4 (en) 2023-12-06
KR20220103707A (en) 2022-07-22
BR112022006085A2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
MX2022002877A (en) Hpk1 antagonists and uses thereof.
MX2022003823A (en) Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof.
MX2023004593A (en) Tyk2 inhibitors and uses thereof.
MX2023003989A (en) Compounds, compositions and methods.
MX2023014120A (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods.
MX2021013193A (en) Substituted cyclolakyls as modulators of the integrated stress pathway.
MX2021012216A (en) Stat degraders and uses thereof.
MX2022005232A (en) Small molecule degraders of helios and methods of use.
MX2023005484A (en) Carbamoyl phenylalaninol analogs and uses thereof.
TW200621244A (en) Modulators of muscarinic receptors
MY202185A (en) Carbamoyl phenylalaninol compounds and uses therof
CU20210099A7 (en) NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES
ZA202100672B (en) Further substituted triazolo quinoxaline derivatives
MX2020006355A (en) Substituted pyrrolidine amides ii.
MX2021000762A (en) Substituted triazolo quinoxaline derivatives.
MX2023009060A (en) Gpr84 antagonists and uses thereof.
PH12019550272A1 (en) Liver x receptors (lxr) modulators
NO20073369L (en) Modulators of muscarinic receptors
MX2021014585A (en) Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease.
MX2023005408A (en) Compounds and their use in treatment of tachykinin receptor mediated disorders.
MX2022000203A (en) Sustained release compositions of endoxifen.
WO2018081168A3 (en) Benzothiophene-based selective mixed estrogen receptor downregulators
MX2023009059A (en) Gpr84 antagonists and uses thereof.
MX2020006348A (en) Substituted pyrrolidine amides i.
MX2021003888A (en) Novel compounds useful for treating cardiovascular diseases.